X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, approved by X4's Compensation Committee, consist of options to purchase 708,236 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.8001 per share, equal to the closing price on July 31, 2024. The options will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement material to new employees.
X4 Pharmaceuticals (Nasdaq: XFOR), un'azienda concentrata sul miglioramento della vita delle persone affette da rare malattie del sistema immunitario, ha annunciato l'emissione di premi di incentivazione per nuovi dipendenti nell'ambito del suo Piano di Incentivazione Equity del 2019. I premi, approvati dal Comitato Compensazione di X4, consistono in opzioni per acquistare 708.236 azioni del comune di X4. Queste opzioni hanno una durata di dieci anni e un prezzo di esercizio di $0.8001 per azione, corrispondente al prezzo di chiusura del 31 luglio 2024. Le opzioni matureranno in quattro anni, con il 25% che matura dopo 12 mesi e il restante che matura mensilmente nei 36 mesi successivi, soggetto a proseguimento dell'impiego. Questa concessione è in linea con la Regola di Quotazione Nasdaq 5635(c)(4) per indennizzi materiali ai nuovi dipendenti.
X4 Pharmaceuticals (Nasdaq: XFOR), una empresa dedicada a mejorar la vida de las personas con enfermedades raras del sistema inmunológico, ha anunciado la emisión de premios de inducción para nuevos empleados bajo su Plan de Incentivos de Capital de Inducción 2019. Los premios, aprobados por el Comité de Compensación de X4, consisten en opciones para comprar 708,236 acciones ordinarias de X4. Estas opciones tienen un plazo de diez años y un precio de ejercicio de $0.8001 por acción, equivalente al precio de cierre del 31 de julio de 2024. Las opciones se adquirirán en cuatro años, con un 25% adquirido después de 12 meses y el resto adquirió mensualmente durante los siguientes 36 meses, sujeto a la continuación del empleo. Esta concesión está en línea con la Regla de Cotización de Nasdaq 5635(c)(4) para inducción material a nuevos empleados.
X4 제약(X4 Pharmaceuticals, Nasdaq: XFOR)은 희귀 면역 체계 질환을 앓고 있는 사람들의 삶을 개선하는 데 중점을 두고 있는 회사로, 2019년 유도 주식 인센티브 계획에 따라 신입 직원에게 유도 상금을 발급한다고 발표했습니다. 이 상금은 X4의 보상위원회에 의해 승인되었으며, X4의 보통주 708,236주를 구매할 수 있는 옵션으로 구성되어 있습니다. 이 옵션의 유효 기간은 10년이며, 행사가격은 주당 $0.8001로, 2024년 7월 31일의 종가와 동일합니다. 옵션은 4년에 걸쳐 권리가 부여되며, 12개월 후에 25%가 권리가 부여되고 나머지는 다음 36개월 동안 매달 권리가 부여되며, 계속 고용되어야 합니다. 이 부여는 신입 직원에게 중요한 유도에 대한 Nasdaq 상장 규칙 5635(c)(4)와 일치합니다.
X4 Pharmaceuticals (Nasdaq: XFOR), une société dédiée à l'amélioration de la vie des personnes atteintes de maladies rares du système immunitaire, a annoncé l'émission de primes d'incitation à de nouveaux employés dans le cadre de son Plan d'Incitation au Capital d'Induction de 2019. Les primes, approuvées par le Comité de Rémunération de X4, consistent en des options d'achat de 708.236 actions ordinaires de X4. Ces options ont une durée de dix ans et un prix d'exercice de $0.8001 par action, égal au prix de clôture du 31 juillet 2024. Les options seront acquises sur quatre ans, avec 25% acquises après 12 mois et le reste acquis mensuellement au cours des 36 mois suivants, sous réserve de l'emploi continu. Cette attribution est conforme à la Règle de Cotation de Nasdaq 5635(c)(4) pour l'incitation matérielle aux nouveaux employés.
X4 Pharmaceuticals (Nasdaq: XFOR), ein Unternehmen, das sich darauf konzentriert, das Leben von Menschen mit seltenen Erkrankungen des Immunsystems zu verbessern, hat die Gewährung von Anreizprämien an neue Mitarbeiter im Rahmen seines Anreiz-Aktienoptionsplans 2019 angekündigt. Die Prämien, die vom Vergütungsausschuss von X4 genehmigt wurden, bestehen aus Optionen zum Kauf von 708.236 Aktien des Stammkapitals von X4. Diese Optionen haben eine Laufzeit von zehn Jahren und einen Ausübungspreis von 0,8001 $ pro Aktie, was dem Schlusskurs am 31. Juli 2024 entspricht. Die Optionen werden über vier Jahre verbraucht, wobei 25% nach 12 Monaten und der Rest monatlich über die folgenden 36 Monate, abhängig von der fortgesetzten Beschäftigung, fällig wird. Diese Gewährung steht im Einklang mit der Nasdaq-Notierungsregel 5635(c)(4) für materielle Anreize für neue Mitarbeiter.
- Attraction of new talent through equity incentives
- Alignment of employee interests with company growth through stock options
- Potential dilution of existing shareholders' equity
- Low stock price of $0.8001 per share may indicate market challenges
BOSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on July 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 708,236 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI™ (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
How many shares of X4 Pharmaceuticals (XFOR) were granted as inducement awards?
What is the exercise price of the stock options granted by X4 Pharmaceuticals (XFOR) on July 31, 2024?
What is the vesting schedule for the inducement stock options issued by X4 Pharmaceuticals (XFOR)?
Under which plan did X4 Pharmaceuticals (XFOR) issue these inducement awards?
